You would have to think that a large cap pharma would be prepared to pay 2 to 3 times the Principia outlay (assuming the trial results are as good as we think they will be).
My opinion only. DYOR.
Ann: First patient treated in ACW XanaMIA ph 2b Alzheimers trial, page-22
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.57M | |||
| Open | High | Low | Value | Volume |
| 2.6¢ | 2.7¢ | 2.5¢ | $151.1K | 5.814M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 2007355 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.6¢ | 396794 | 2 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| ACW (ASX) Chart |